Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Sibylle C MellinghoffSandra RobrechtRosanne SpruteLeonie MayerLeonie M WeskammChristine DahlkeHenning GruellFinn TeipelHans Anton SchlößerKlara SiepmannMartin ThelenAnna-Maria FinkKirsten FischerFlorian KleinMarylyn Martina AddoAndroniki KolovouOliver Andreas CornelyBarbara EichhorstMichael HallekPetra LangerbeinsPublished in: European journal of haematology (2024)
Our data reveal an increase of cellular and humoral immune response in CLL patients after fourth COVID-19 vaccination combined with SARS-CoV-2 infection, even in those undergoing B cell-depleting treatment. Patients with prior vaccination failure now show a specific IgG response. Future research should explore the duration and effectiveness of hybrid immunity considering various factors like past infection and vaccination rates, types and numbers of doses, and emerging variants.
Keyphrases
- sars cov
- chronic lymphocytic leukemia
- immune response
- respiratory syndrome coronavirus
- end stage renal disease
- ejection fraction
- coronavirus disease
- newly diagnosed
- randomized controlled trial
- chronic kidney disease
- systematic review
- peritoneal dialysis
- gene expression
- dendritic cells
- genome wide
- single cell
- toll like receptor
- machine learning
- combination therapy
- replacement therapy
- smoking cessation
- data analysis